BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM
- Acoramidis is the first and only approved ATTR-CM treatment in the U.S., EU, UK and Japan that all have a label specifying near-complete stabilization (≥90%)
- Relative increases in serum TTR concentrations resulting from greater TTR stability have been associated with reduced risk of all-cause and cardiovascular mortality in the general population in recent literature1
- BridgeBio will receive royalties in a tiered structure beginning in the low-thirties percent on sales of Beyonttra in the UK
PALO ALTO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ('BridgeBio' or the 'Company'), a new type of biopharmaceutical company focused on genetic diseases, today announced the Medicines and Healthcare products Regulatory Agency has granted marketing authorization in the United Kingdom (UK) for acoramidis, under the brand name BEYONTTRA®, for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered near-complete (≥90%) transthyretin (TTR) stabilizer. ATTR-CM is a progressive fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure. Bayer will be responsible for all commercial activity for acoramidis in the UK.
'ATTR-CM is a progressive and debilitating disease that poses significant challenges not only for patients but also for the healthcare systems. The condition profoundly impacts patients' quality of life. Symptoms attributable to amyloidosis are usually nonspecific, varied and associated with low awareness, frequently resulting in delayed or completely missed diagnosis,2 which may lead to delayed treatment and a worse prognosis. In the absence of intervention, ATTR-CM causes progressive heart failure leading to increased hospitalizations and escalating healthcare costs and is ultimately fatal,3-5' said Julian Gillmore, M.D., Ph.D., University College London's Centre for Amyloidosis, UK. 'The UK authorization of Beyonttra is welcome news for eligible patients living with the condition. Physicians in the UK now have another treatment option to slow the progression of symptoms and improve outcomes for patients with ATTR-CM.'
The approval in the UK is based on results of the pivotal ATTRibute-CM Phase 3 study of acoramidis, which showed clear benefits on cardiovascular outcomes. ATTRibute-CM evaluated the efficacy and safety of acoramidis in 632 participants with symptomatic ATTR-CM, associated with either wild-type or variant TTR who were randomized 2:1 to receive acoramidis or placebo for 30 months. The study met its primary clinical endpoints at month 30 by significantly reducing cardiovascular-related hospitalization, improving survival, and preserving functional capacity and quality of life for patients.
'We are proud to add another approval for acoramidis and thrilled that patients in the UK will now have access to BEYONTTRA since they are in great need of new disease-modifying treatments for their condition,' said Jonathan Fox, M.D., Ph.D., President and Chief Medical Officer of BridgeBio Cardiorenal. 'We appreciate the time and commitment of every clinical trial participant and their families, and the dedicated support of the physicians and scientists involved in the clinical program. This important milestone would not have been possible without their commitment to the program. We look forward to extending our collaboration with our European partner, Bayer, to serve ATTR-CM patients across the UK and the rest of Europe, and will continue to work towards reaching patients in as many regions as possible around the world.'
Acoramidis was approved as Attruby™ by the U.S. FDA in November 2024 and was approved as BEYONTTRA by the European Commission in February 2025 and the Japanese Ministry of Health, Labour, and Welfare (MHLW) Agency in March 2025 with all labels specifying near-complete stabilization of TTR.
In March 2024, BridgeBio and Bayer initiated a collaboration for acoramidis, which granted Bayer exclusive commercialization rights in Europe. Based on terms of the licensing agreement, BridgeBio will receive royalties in a tiered structure beginning in the low-thirties percent on sales of acoramidis in the UK following initiation of commercialization efforts.
1Christoffersen M et al. Transthyretin Tetramer Destabilization and Increased Mortality in the General Population. JAMA Cardiol. 2024 Dec 4:e244102.
2Rintell et al. Orphanet J Rare Dis. (2021) 16:70. https://doi.org/10.1186/s13023-021-01706-7
3Rozenbaum MH, et al. Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review. Cardiology and therapy. 2021;10:141-59.
4Mallus MT and Rizzello V. Treatment of amyloidosis: present and future. 2023;21;25(Suppl B):B99-B103.
5Jain A, Zahra F. Transthyretin Amyloid Cardiomyopathy (ATTR-CM). Updated 27 April 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK574531/ Last accessed: March 2025.
About BEYONTTRA
BEYONTTRA is an orally administered near-complete (≥90%) stabilizer of transthyretin (TTR) indicated for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). For full prescribing information, please refer to the Summary of Product Characteristics (SmPC) on the Medicines and Healthcare products Regulatory Agency website at https://products.mhra.gov.uk/.
About Attruby™ (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).
▼: This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
About BridgeBio
BridgeBio is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.
BridgeBio Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as 'anticipates,' 'believes,' 'continues,' 'estimates,' 'expects,' 'hopes,' 'intends,' 'may,' 'plans,' 'projects,' 'remains,' 'seeks,' 'should,' 'will,' and variations of such words or similar expressions. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements, including statements relating to the impact of Beyonttra on clinical outcomes; and the potential benefits of Beyonttra, including its ability to reduce cardiovascular-related hospitalization, improve survival, and preserve functional capacity and quality of life, reflect BridgeBio's current views about its plans, intentions, expectations, and strategies, which are based on the information currently available to BridgeBio and on assumptions BridgeBio has made. Although BridgeBio believes that its plans, intentions, expectations, and strategies, as reflected in or suggested by these forward-looking statements, are reasonable, BridgeBio can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties, and assumptions, including, but not limited to, the risks associated with BridgeBio's dependence on third parties for development, manufacture, and commercialization activities related to Beyonttra; government and third-party payor actions; risks and uncertainties relating to competitive products and other changes that may limit demand for Beyonttra; the risk that regulatory authorities may require additional studies or data to support the continued commercialization of Beyonttra; the risk that drug-related adverse events may be observed during commercialization or clinical development; the risk that data and results may not meet regulatory requirements or otherwise be sufficient for further development, regulatory review, or approval; the risk of other regulatory agencies not agreeing with BridgeBio's regulatory approval strategies, components of BridgeBio's filings (such as clinical trial designs, conduct, and methodologies), or the sufficiency of data submitted; the continuing success of its collaborations, including compliance with applicable regulations for the purchase, distribution, storage, export, and sale of active pharmaceutical ingredients and medicinal products; uncertainty regarding any impacts due to global health emergencies, including delays in regulatory review, manufacturing, and supply chain interruptions; adverse effects on healthcare systems and disruption of the global economy; the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and in Israel and the Gaza Strip; and increasing rates of inflation and changing interest rates on BridgeBio's business operations and expectations. These risks, as well as those set forth in the Risk Factors section of BridgeBio's most recent Annual Report on Form 10-K and its other filings with the U.S. Securities and Exchange Commission, should be carefully considered. Moreover, BridgeBio operates in a highly competitive and rapidly changing environment, in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of BridgeBio's management as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, BridgeBio assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.
BridgeBio Media Contact:
Bubba Murarka, EVP Communications
Chinmay Shukla, VP Strategic Finance
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Why Is Wall Street So Bearish on Plug Power? There's 1 Key Reason.
Key Points One analyst gives the stock a price target of $0.75. Profitability concerns create ongoing risks for investors. 10 stocks we like better than Plug Power › Plug Power (NASDAQ: PLUG) has captivated growth investors for decades. The company specializes in producing hydrogen fuel systems, a segment of the market that could see massive growth rates throughout the rest of this century. There should be plenty of near-term growth, too. According to research published in 2024 by Bloomberg, clean hydrogen fuel demand is expected to "skyrocket 30-fold to 16.4 million metric tons per year by 2030." But investors aren't all on board: Some Wall Street analysts remain bearish on the stock. Morgan Stanley analysts, for example, rate PLUG stock as a sell with a price target of just $0.75 -- roughly 50% below the current share price. This is the No. 1 problem with Plug Power stock today While industry forecasts call for major hydrogen fuel demand growth, the technology is still largely uncompetitive versus traditional fossil fuels, and even versus renewable sources like wind and solar. As Bloomberg's research highlights, demand growth forecasts will be very sensitive to changes in government regulations and subsidies -- two components that are critical in making hydrogen fuel economically viable. A lack of economic viability has consistently reduced demand for Plug Power's products over the decades. The company itself has often been reliant on large government subsidies to remain financially afloat. This is exactly what Wall Street analysts are worried about. Morgan Stanley's analysts have been sounding the alarm since 2023. "We see significant risk around PLUG's business model," they wrote then. "On paper, PLUG's strategy makes sense to us, but we have reduced confidence in the company's ability to execute on that strategy barring a potential dilutive capital raise." Morgan Stanley's concerns were prescient. Since that time, Plug Power has nearly doubled its share count, massively diluting shareholders in an attempt to stay financially viable. Today, the company continues to post negative net incomes quarter after quarter. The future is bright for hydrogen fuel. But Plug Power's lack of profitability continues to concern analysts, and is something investors have to watch. Should you buy stock in Plug Power right now? Before you buy stock in Plug Power, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Plug Power wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Ryan Vanzo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Is Wall Street So Bearish on Plug Power? There's 1 Key Reason. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
3 Serious Tesla Problems Investors Aren't Talking Enough About
Key Points Lawsuits continue to mount for Tesla and Elon Musk. There has been a flurry of executive departures from the company. Losing revenue from zero-emission credit sales is a big blow to EV makers. These 10 stocks could mint the next wave of millionaires › It's been a bumpy ride for Tesla (NASDAQ: TSLA) investors in 2025. The EV maker is feeling the heat from all angles: media, consumers, analysts, you name it. But for all the consumers leaving the brand, and the media frustrated with Elon Musk's political antics, there are a few problems that have gone unnoticed. Let's take a look at recent lawsuits, the talent exodus, and the loss of valuable zero-emissions credit sales. 1. Lawsuits keep mounting Just earlier this month, Elon Musk and Tesla were sued by shareholders who accused them of securities fraud for hiding the serious risk its self-driving vehicles posed. The proposed class action lawsuit was filed earlier this month and was a black eye after the automaker's first public test of its robotaxis in late June in Austin, Texas. These lawsuits have a wide range of driving forces, many seemingly from the actions of Musk himself. In fact, as of August 2023, Tesla was already party to over 1,750 lawsuits, a big chunk of them in China, where the company is already struggling to protect market share and profits amid a brutal price war and increased competition from domestic Chinese automakers. Also earlier this month, a federal jury found Tesla partly liable in a 2019 car crash that killed a pedestrian and left another badly injured while the automobile was on Autopilot. The jury awarded the plaintiffs $43 million in compensatory damages for pain and suffering, plus another $200 million in punitive damages. These lawsuits are certainly difficult to keep track of, but investors would be wise to remember that these lawsuits are adding up, and some can be very costly in brand image or directly through damages. 2. A concerning talent exodus Amid the flurry of negative news facing Tesla, many investors brushed off the peppering of executive departures throughout the year. But this is a talent exodus that has become, and should be, concerning to investors. Here's a look at key departures, to name a few: Omead Afshar (VP/Head of Sales and Manufacturing, North America/Europe) Milan Kovac (Head of Optimus Humanoid Robot Team) Vineet Mehta (Head of Battery Architecture) Troy Jones (VP of Sales, Service, and Delivery, North America) Pete Bannon (VP of Hardware Engineering, Chip Tech, and Dojo Supercomputer) Piero Landolfi (Director of Service, North America) Those were just a handful of high-profile executives and key personnel departing, and its leaders in key areas such as service, sales, engineering, and even the robotics team. The departures raise concerns about Tesla's leadership, operational challenges, and its current ability to remain competitive. 3. Companies in this space are losing valuable revenue To say that Tesla and some of its EV competitors are about to lose a significant revenue source is putting it lightly. That's right: Tesla, Lucid, and Rivian, among others, are about to see billions of dollars in revenue disappear seemingly overnight as U.S. policy essentially ends the zero-emission credit market. Essentially, the government formerly penalized automakers with lower average fuel economy, or those that produced more gasoline-guzzling vehicles and fewer EVs, but that is no longer. Without penalties being enforced, those companies failing to meet emissions standards are no longer incentivized to purchase zero-emission credits from EV makers to meet standards. And as the market for those zero-emission credits dried up, so too did a significant chunk of revenue for EV makers with a surplus of such credits. The National Highway Traffic Safety Administration (NHTSA) has already stopped issuing compliance letters to automakers that violate the fuel economy standards. What it all means When it rains, it pours -- at least that's how it seemed for most of Tesla's developments this year. But savvy investors would be wise to keep abreast of developments with Tesla lawsuits and its massive talent exodus, in addition to losing valuable revenue from zero-emission credits. These haven't been covered enough and raise uncertainty surrounding the EV maker. Long-term investors should try and weather the storm and stay focused on the company's business long term. But it's also fair to say Tesla is at a crossroads with its future strategy, and investors will have to revisit their investment thesis to see if they are still aligned. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $472,031!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $43,882!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $671,466!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of August 18, 2025 Daniel Miller has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool has a disclosure policy. 3 Serious Tesla Problems Investors Aren't Talking Enough About was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Should You Buy Shopify Stock After Its Post-Earnings Pop?
Key Points Shopify's revenue growth is accelerating. The company is adding new features for AI tools, advertising, and a consumer shopping app. The stock trades at a wildly expensive valuation today. 10 stocks we like better than Shopify › Investors in Shopify (NASDAQ: SHOP) have gone on a wild ride in the last five years. The e-commerce software and payments platform saw surging growth and a meteoric rise in its stock price during the COVID-19 pandemic before crashing down to earth in 2022. Shares went from close to $170 to below $30 in less than two years. Now, the stock is rising again, hitting recent highs of over $150 after positing strong growth yet again in the second quarter of 2025. But still, Shopify shareholders remain underwater if they bought at most points in 2021. Does that mean the stock is a buy today after its recent post-earnings pop? Accelerating global growth Even though inflation has come down and consumer spending growth has slowed in the United States, Shopify's revenue growth is accelerating. It is doing so by gaining market share of e-commerce and retail spending in the United States while expanding to new markets such as Europe. Last quarter, revenue grew 31% year over year to $2.68 billion, compared to 21% growth in the year-ago period. Payment volume in Europe -- which correlates closely to revenue -- grew 42% and greatly outpaced overall sales. Why are more and more businesses such as Starbucks and Canada Goose adopting Shopify's software tools? Because of its wide breadth of products that help grow their businesses, outsourcing an important function (having your own online storefront) to a trusted third party. Not every sale is going to come from Amazon, while some companies don't want to sell on broad-based marketplaces at all. Shopify's tools help businesses process payments and grow earnings, which leads to more revenue for Shopify as it takes a cut of every transaction. This is a self-reinforcing cycle that has helped Shopify's revenue grow from well under $1 billion to $10 billion in less than 10 years, making it one of the fastest-growing businesses in the world. Expanding products and margin expansion potential Shopify is not resting on its laurels. It is building new services to grow with its customer base. This includes connections with artificial intelligence (AI) query services to help pull products from its commerce partners when users ask chatbots questions. Everything comes back to driving more sales through e-commerce websites, which has driven total payment volume on Shopify partner websites from under $1 billion in 2012 to $327 billion in the last 12 months. What's more, Shopify is now moving beyond payments for commerce partners through Shopify Campaigns, an advertising service. These campaigns can go on traditional channels such as Google or Instagram but also on the native Shop application. Shop is a mobile app from Shopify that acts as an aggregator for its e-commerce partners, similar to Amazon. This is a bold new venture in building a consumer-facing application but greatly expands Shopify's addressable market. Add everything together along with the core tailwind of its e-commerce market share gains and Shopify should be able to grow its revenue at a double-digit rate for a long while. In 2025, it expects to grow revenue between 25% and 30% compared to 2024. Right now, Shopify's operating margin is 15.4%. As a payments and software company with low overhead, increasing scale should lead to improving profit margins for Shopify in the years to come. This can help underlying earnings grow even faster than revenue. Should you buy Shopify stock? After looking through the financials, it is clear that Shopify is a great business. This is why the stock price is up 5,000% since its initial public offering (IPO) around 10 years ago. That does not necessarily make the stock a buy, though. Shopify's stock trades at a forward price-to-earnings ratio (P/E) of about 76. This metric takes the current market cap of $185 billion and divides it by consensus estimates of $1.84 per share for net income over the next 12 months. This is already factoring in Shopify's expected strong revenue and earnings growth in the coming quarters. It will be many years before this lofty P/E ratio gets down to the average level of 20 to 30 for large-cap stocks listed in the United States. At a market cap pushing $200 billion and only $10 billion in trailing revenue, Shopify stock looks overvalued, even though the business is firing on all cylinders. You should avoid buying shares of this company after its post-earnings pop. Should you invest $1,000 in Shopify right now? Before you buy stock in Shopify, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Shopify wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Brett Schafer has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Shopify, and Starbucks. The Motley Fool has a disclosure policy. Should You Buy Shopify Stock After Its Post-Earnings Pop? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
